Pfizer (PFE)
22.12
+0.21 (0.96%)
NYSE · Last Trade: Apr 15th, 1:27 AM EDT
Detailed Quote
Previous Close | 21.91 |
---|---|
Open | 22.08 |
Bid | 22.00 |
Ask | 22.07 |
Day's Range | 21.87 - 22.23 |
52 Week Range | 20.92 - 31.54 |
Volume | 61,903,903 |
Market Cap | 124.02B |
PE Ratio (TTM) | 15.69 |
EPS (TTM) | 1.4 |
Dividend & Yield | 1.680 (7.59%) |
1 Month Average Volume | 68,562,877 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation, Chevron Corporation, and Stryker Corporation, as well as two micro-cap stocks, Value Line, Inc. and Sypris Solutions, Inc.
Via Talk Markets · April 14, 2025
Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · April 14, 2025
Stocks are firmly higher Monday, as a surprise tariff exemption from President Donald Trump sparked a rally in the tech sector.
Via Talk Markets · April 14, 2025
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.
Via Stocktwits · April 14, 2025
Pfizer bows, but is not entirely out of the GLP-1 race.
Via The Motley Fool · April 14, 2025
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.
Via Benzinga · April 14, 2025
The social media giant acquired Instagram in 2012 for $1 billion and WhatsApp in a highly competitive bid in 2014 for a whopping $19 billion, beating Google to the punch.
Via Stocktwits · April 14, 2025
A groundbreaking study published in the International Journal of Cardiovascular Research & Innovation reveals alarming long-term heart risks linked to COVID-19 mRNA vaccines, challenging official narratives and raising urgent safety concerns. Contact: Lynne@imahealth.org
Via Newsworthy · April 14, 2025
Pfizer has ended development of danuglipron, an oral GLP-1 drug for weight management, citing clinical data and regulatory input.
Via Benzinga · April 14, 2025
Baristas must wear a solid black top and a denim bottom in any shade of khaki, blue, or black.
Via Stocktwits · April 14, 2025
The company plans to file a certification of dissolution with the Secretary of the State of Delaware in the third quarter of 2025, provided that stockholders authorize the decision at its annual meeting of stockholders on June 5.
Via Stocktwits · April 14, 2025
According to Pfizer, the reported patient’s liver enzymes “recovered rapidly” after they stopped taking the company’s experimental weight loss pill.
Via Stocktwits · April 14, 2025
The company is continuing to test a daily pill that blocks GIPR.
Via Investor's Business Daily · April 14, 2025
Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management.
By Pfizer Inc. · Via Business Wire · April 14, 2025
April 14, 2025 -- Breast Cancer Patients Can Save Thousands Monthly with Trusted Generic "Palnat" at Just $4.38 Per Capsule
Via 24-7 Press Release · April 14, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · April 12, 2025
Via The Motley Fool · April 12, 2025
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Friday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · April 11, 2025
Massive container ports and supply chains worldwide are bracing for impact as broad U.S. import tariffs reshape commerce.
Via Talk Markets · April 11, 2025
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
Via Benzinga · April 11, 2025
Though the stock market is still historically pricey, a few phenomenal bargains have cropped up.
Via The Motley Fool · April 11, 2025
Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.
Via Stocktwits · April 10, 2025
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · April 10, 2025
A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries. This added layer of uncertainty reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains.
Via StockStory · April 10, 2025